It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Associate Professor Julian Elliott, Executive Director of the National COVID-19 Clinical Evidence Taskforce, said the evidence indicates hydroxychloroquine is potentially harmful and no more effective than standard care in treating patients with COVID-19.
‘We have reviewed all the scientific data around hydroxychloroquine and we can now say, definitively, that hydroxychloroquine should not be used as a treatment for anyone with COVID-19,’ he said.
‘There is now sufficient data for us to make a very clear and strong recommendation. In this instance, that is based on data from randomised controlled trials that enrolled nearly 6000 patients.
‘This is a substantial amount of very high-quality scientific data upon which we’ve based the recommendation.
the odds of hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16). There were no cardiac side effects. Conclusions: Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.
A retrospective study looks backwards and examines exposures to suspected risk or protection factors in relation to an outcome that is established at the start of the study. Many valuable case-control studies, such as Lane and Claypon's 1926 investigation of risk factors for breast cancer, were retrospective investigations. Most sources of error due to confounding and bias are more common in retrospective studies than in prospective studies. For this reason, retrospective investigations are often criticised. If the outcome of interest is uncommon, however, the size of prospective investigation required to estimate relative risk is often too large to be feasible. In retrospective studies the odds ratio provides an estimate of relative risk. You should take special care to avoid sources of bias and confounding in retrospective studies.
Is hydroxychloroquine classified as a poison?
Can you cite a source?
It has been in Melbourne to help implement its Biosecurity act.
I heard about one pharmacy, yes. I've also heard of pharmacies refusing to fill opioid and contraception prescriptions too. They've been sued on occasion.
What about some pharmacies for the first time over ruling a doctors prescription and denying filling orders for HCQ?